Headquartered in San Diego, CA Fiscal year ends December NASDAQ: VKTX vikingtherapeutics.com
Viking Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for obesity and metabolic disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous injectable and oral tablet formulations for the treatment of obesity. VK2735 is currently in Phase 3 clinical trials (VANQUISH program) for the subcutaneous formulation and preparing for Phase 3 initiation of the oral formulation. Viking is also advancing VK3019, a dual amylin and calcitonin receptor agonist (DACRA) for obesity currently in Phase 1, as well as VK2809, a thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD). The company generates no revenue and funds its operations through equity financing. Viking trades on the Nasdaq under the ticker VKTX. Updated
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day’s action on the companies themselves rather than on any broader…
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn’t selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.21, down 59%, while Viking Therapeutics…
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the…
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble…
FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are…
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Viking Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for obesity and metabolic disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous injectable and oral tablet formulations for the treatment of obesity.
The Wall Street consensus 12-month price target for VKTX is $94.71. VKTX price prediction →
